ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
about
Tackling ALK in non-small cell lung cancer: the role of novel inhibitorsCancer Evolution and the Limits of Predictability in Precision Cancer MedicineThe regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceCrizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancerThe Evolution of Therapies in Non-Small Cell Lung CancerOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationStructural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLCSecond- and third-generation ALK inhibitors for non-small cell lung cancerAlectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistanceTargeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic HypogonadismCotargeting MNK and MEK kinases induces the regression of NF1-mutant cancersDetection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAQuantitative proteomics in lung cancer.Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.The EML4-ALK oncogene: targeting an essential growth driver in human cancer.Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerFirst-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsDiscovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCNKRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyResisting Resistance: Targeted Therapies in Lung Cancer.Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathwaySynergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphomaDetecting and targetting oncogenic fusion proteins in the genomic era.Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.Anaplastic lymphoma kinase: Role in cancer and therapy perspective.The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions.Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.EML4-ALK-positive lung adenocarcinoma presenting an unusual metastatic pattern in a 29-year-old woman who is alive and well in her third year follow up:A case report.
P2860
Q26740329-718AC3A3-72D7-44DA-9A13-65FEBC3BDF00Q26767415-9C84B4D3-D8E8-4DC9-90C7-C6E437D7C6A8Q26770643-52E7F54C-B2C7-422B-A959-B89EDD6F9CD0Q26775347-43871C38-FAB2-4F47-8624-34DDA7CEEDCDQ26778500-71354559-00F6-4DF5-84B0-BF05A1FD2CEFQ26786932-86044E20-12F6-4FFE-B3A0-7AA41A0D0D61Q26795556-3F3D2655-DC05-46A7-9D15-C8CACB3D4430Q27853214-A209C6CA-D958-457C-ADA4-D0968F963D3AQ27853373-B499EAF0-2001-4577-A637-04E70A681EBBQ28068643-26B0B990-85A2-4210-B647-D623DDC4CB83Q28072496-23B8E390-5D9D-4C45-BE89-43A198C19C82Q28081606-E1DE6C45-6E44-4A6D-9DA4-63FC515F4167Q28547121-728FF6AF-C223-47EE-BBBA-A81918701408Q28829666-2F420E52-5B79-493B-B852-0A5CDAF4429AQ33737740-C91D1331-A56E-4167-ACEA-0932FA1F6F41Q33796358-C19911A3-55FE-419B-8BD5-9311408AF30CQ35057308-353F8969-69B9-47D1-A10C-8A3050DF85BEQ35549714-6ADC7371-53F1-4534-83BB-7D858CF95321Q35631006-48332C94-01AC-43CC-9016-824618680A26Q35751883-915C7B81-F4F6-4E54-8272-A5F3808DF458Q36145016-E36435D2-6D9C-404F-98E9-2E9F30927136Q36432094-8B28BA99-0F09-4C18-ADE6-752F54CCD239Q36675561-00A53A3E-2180-4BEA-82A6-6745CFE25E9CQ37003600-2A8C33EC-6AEA-4E41-9912-3990AAAA08BCQ37051546-1894759A-ED45-4572-8A00-6F453C85047FQ37305906-F08AF5D7-7D4F-459B-8405-6F7F7B117780Q37353957-DA13EF60-F94F-4FA8-9B78-7B607F33CFB6Q37359022-E8618C1B-423F-42B9-A7BC-9068A5959D5BQ37388238-DD4A3C4B-EB59-4D01-AAA8-BDFE6581A551Q37644847-B8DB9E09-6138-43D3-B0D0-D7A29B75E061Q37687313-BADA57C8-A6B1-4A6A-B706-C4AF3163EDFEQ38336067-0D524FA7-DF1F-4EBF-9319-9AFAF6E26C7BQ38459398-B185ECA0-3F63-4AA2-9224-40CFC5BE327AQ38461723-ADCE1147-CD80-403A-BF14-035E0AAC0F69Q38623421-29DD68C0-2061-4923-8F6F-61147F055FEAQ38635259-FC41D663-7A7A-4694-A2EF-BDEE0CEDE9BAQ38730533-C8291B52-CA39-4869-A385-66519EFAEDEFQ38800617-3ED9CEA9-F8AC-4749-BE46-6D7CD2699459Q38956448-A1AEFD33-26CA-46F0-B212-EBF0CF80E3E7Q41492859-6BB07DD0-011E-4464-A11E-31CF2366078C
P2860
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
@ast
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
@en
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
@nl
type
label
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
@ast
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
@en
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
@nl
prefLabel
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
@ast
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
@en
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
@nl
P2860
P1476
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
@en
P2093
Alice T Shaw
Mark M Awad
P2860
P304
P577
2014-07-01T00:00:00Z